Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Aug 17 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Doxepin Tablets in two dosages. Doxepin is indicated for treating insomnia and is expected to improve sleep duration and reduce nighttime awakenings. The tablets will be produced at Zydus's facility in Moraiya, and the approval adds to the company's extensive portfolio of drug approvals.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases